KCT0003916招募中未知
A phase 2 trial of pre-phase treatment before R-CHOP chemotherapy in elderly patients with newly diagnosed DLBC
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 65(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1)Extensive, histologically diagnosed, large B-cell lymphoma patients.
- •2) Age 65 or older at the time of diagnosis
- •3) Patients planning R-CHOP chemotherapy
- •4) Second Ann Arbor weapon (bulky = Diameter of 7cm), third or fourth patient
- •5) High intermediate or high risk with International Prognostic Index (IPI)
- •6) Patients who do not have a history of lymphoma before
- •7) Patients who decide to participate in this study voluntarily and agree in writing
排除标准
- •1) CD20-positive widespread histological subtype other than large B-cell lymphoma
- •2) Patients with extensive B-cell lymphoma invading the central nervous system
- •3) A systemic disease in which anti-cancer drugs are administered is inappropriate
- •A. Patients who had clinically significant heart disease (hypertensioned congestive heart failure, syndrome coronary heart disease, cardiac arrhythmia) or myocardial infarction within the past six months.
- •B. Severe neurological and psychiatric disorders
- •C. Severe Active Infection
- •D. A medical condition that is difficult to perform other clinical trials.
- •4) If the drug used in this study is allergic to it
- •5) Failure to understand or disagree with written consent
研究者
相似试验
已完成
2 期
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000030457Fujita Health University School30
招募中
2 期
Phase II study of pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantatioPatients with low-level positive cytomegalovirus antigenemia after allogeneic hematopoietic stem cell transplantationJPRN-UMIN000004792Dept of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan20
进行中（未招募）
1 期
Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30
招募中
2 期
High humidity decreases symptomatic patent ductus arteriosusJPRN-jRCT1032190068Hirata Michisato30
进行中（未招募）
不适用
Phase II clinical study for the therapy of cystic fibrosis patients with aspecific mutatioCystic fibrosis patients with F508del-CFTR in homozygous or compound heterozygous with Class I or II mutationsEUCTR2013-001258-82-ITEuropean Institute for Cystic Fibrosis Research (IERFC)